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Abstract 
Secondary central nervous system (CNS) involvement is an uncommon event that tipically occurs 
early in the natural history of diffuse large B-cell lymphoma (DLBCL) and presents as 
leptomeningeal dissemination in two-thirds of cases. The prognosis of this event is dismal and 
treatment options are meager. Although major validated risk factors for CNS dissemination are 
clinical, concomitant MYC/BCL2 rearrangements as well as MYC/BCL2 protein expression have 
been recently associated with an increased risk of this complication.  
Here we present the first case, to our knowledge, of a MYC/BCL6-positive double-hit DLBCL 
relapsing in the leptomeninges that achieved an outstanding durable remission with single-agent 
lenalidomide following salvage chemotherapy. 
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Introduction 
In September 2014, a 73-year old man was admitted at our institution complaining of lumbar back 
pain and paresthesias of lower extremities 2 months after the completion of a first-line 
immunochemotherapy treatment program. The patient was previously diagnosed with a stage IA 
bulky, germinal center B-cell type (GCB) (CD10+, BCL-6+, BCL-2+ by immunohistochemistry), 
DLBCL, harboring concurrent MYC and BCL6 rearrangements and due to a past medical history of 
ischaemic heart disease he had received 6 cycles of rituximab, cyclophosphamide, vincristine, 
prednisone and nonpegylated liposomal doxorubicin with the achievement of a complete response.  
At time of admission, neurological examination and laboratory tests were  negative. A whole-spine 
MRI was performed showing a leptomeningeal enhancement from T6 to the medullary cone on a 
T1-weighted image; the concurrent MRI of the brain was negative. The patient underwent a lumbar 
puncture and the cerebrospinal fluid (CSF) findings were consistent with a leptomeningeal 
recurrence of a DLBCL. Indeed, the CSF analysis by flow cytometry revealed a CD19, CD20, 
CD79a positive cell population with a cell count of 312 cells/µl. Alike, the cytology of the CSF 
demonstrated large malignant lymphoid cell with basophilic cytoplasm and prominent nucleoli 
(Figure 1). A systemic relapse was excluded through total body CT scanning and bone marrow 
biopsy.  
Based on the CNS relapse, the patient started receiving a salvage treatment consisting of high dose 
methotrexate and cytarabine alternating with be-weekly administration of intrathecal liposomal 
cytarabine for 4 cycles with a prompt recover of symptoms. Major reported toxicities were G2 oral 
mucositis after the first cycle and G4 pancytopenia after the third cycle and they were successfully 
handled through supportive care. At the end of salvage treatment, a good response was attained with 
only 1 cell/µl identified by both CSF flow cytometry and cytology; accordingly, the spinal MRI 
revealed a significant reduction of pathological leptomeningeal contrast enhancement.  
Given patient’s refusal to receive consolidation whole-brain RT as well as the high-risk disease we 
decided to administer lenalidomide single-agent at a dose of 15 mg daily for 21 consecutive days 
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every 4 weeks  as maintenance therapy.  The dose was reduced to 10 mg after the second cycle due 
to G4 neutropenia and infectious pneumonitis.  A disease assessment performed after 8 cycles of 
lenalidomide showed no evidence of lymphoma on FDG-PET and spinal MRI. Similarly, CSF 
analysis was negative. The treatment with lenalidomide is still ongoing (month +9) and after dose 
reduction is optimally tolerated. 
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Discussion 
Lymphomatous meningitits or lymphoma in the leptomeninges is an uncommon but almost 
universally fatal complication occurring in 5 to 29% of DLBCL patients with a median survival of 
2.2 months [1-3]. Involvement of > 1 extranodal site, of certain extranodal sites such as testes, orbit, 
paranasal sinuses, breast and elevated LDH level are the most reliable risk factors for CNS 
recurrence in the post-rituximab era [4]. Interestingly, kidney and/or adrenal involvement was 
recently added to the five International Prognostic Index factors (age, elevated LDH, poor 
performance status, advanced stage, and involvement of > one extranodal site) into a robust and 
reproducible model for predicting CNS dissemination [5]. 
The best therapeutic approach of lymphomatous meningitits is still an unmet medical need mainly 
due to the poor capability of the drugs, even the most systemically active as the anti-CD20 
rituximab, to effectively cross the blood-brain barrier. Intrathecal administration of 
chemotherapeutic agents including methotrexate and liposomal cytarabine is the preferred treatment 
choice with the aim of relieving patients’ symptoms. Systemic chemotherapy with high dose 
methotrexate and cytarabine as well as radiotherapy are other commonly used treatment options in 
this setting, though associated with high toxicity rates. Moreover, rituximab given intrathecally is a 
promising strategy and is currently under investigation in early phase clinical trials [6]. The 
improved knowledge of the molecular pathogenesis of the disease occurred over recent years has 
provided insights into key molecular pathways and genomic aberrations amenable to small 
molecule targeting. The vast majority of primary CNS lymphoma (PCNSL) expresses MUM-1 
(95%) and BCL6 (50% to 80%) and shares disrupt pathways with ABC-type systemic DLBCL such 
as BCR, NFkB, JAK-STAT, mTOR and PIM kinases [7]. The deregulation of BCR signalling has 
given the rationale to investigate pharmacologic antagonists of the BCR and downstream mediators 
in CNS lymphoma [8]. In this regard, the BTK inhibitor ibrutinib is being evaluated in combination 
with temozolomide, etoposide, doxil, dexamethasone and rituximab (TEDDI-R) in patients with 
untreated and refractory/relapsed PCNSL [9]. In this phase I/II study, all of 5 evaluable patients 
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experienced a tumor reduction after 2 cycles of TEDDI-R, 3 achieved a CR and 1 achieved a PR. Of 
interest, ibrutinib has shown to achieve meaningful CSF concentration.  
In the last decade, also the small molecule lenalidomide has emerged as a highly effective and well-
tolerated compound in refractory/relapsed systemic DLBCL with an antineoplastic effect mediated 
by the downmodulation of MUM1/IRF-4, and subsequently, BCR–dependent NFkB activity [10-
12]. The high expression of MUM-1/IRF-4 in lymphoma involving the CNS and its role in the 
pathogenesis of the disease made it an attractive therapeutical target.  
A couple of clinical reports suggesting a significant role of lenalidomide in aggressive lymphomas 
relapsing at intraocular site have recently been described and, interestingly, lenalidomide has been 
shown to adequately concentrate in the CSF at the 23.3% of serum level [13-14]. Moreover, there is 
early evidence of the activity  of lenalidomide either as monotherapy or as maintenance after 
salvage interventions in patients with refractory/relapsed CNS DLBCL. Among 8 patients treated 
with lenalidomide single-agent, 4 achieved a CR and 3 a PR after 1 month of therapy; for patients 
with inadequate response to lenalidomide, intravenous plus intraventricular rituximab were also 
administered. Likewise, in a cohort of 10 patients receiving maintenance lenalidomide, 5 
maintained their response for ≥ 2 years [15].   
We report herein a case of long-lasting complete response to lenalidomide as maintenance therapy 
after an uncomplete response to salvage chemotherapy in a patient with MYC/BCL6-positive 
double-hit DLBCL with leptomeningeal relapse. The remission is still ongoing at 9 months from 
treatment initiation with a survival outcome superior to those historically reported for this patient’s 
population. The result achieved in our patient is even of greater interest given that he has a GCB-
type DLBCL, whose response rate to lenalidomide has been showed to be lower (9%) than that of 
non-GCB-type (59%) [16]. However, owing to its favorable risk-to benefit ratio as well as its 
activity in the relapsed disease, we decided to give our patient lenalidomide as maintenance therapy.  
The ability of lenalidomide to achieve meaningful CSF concentration along with its mechanism of 
action aimed at targets overexpressed in CNS lymphoma such as MUM1/IRF-4 are potential key 
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elements of the therapeutic activity of the drug. Based on this and previously reported cases, its 
effectiveness across different subtype of NHLs as well as its capability of penetrating the blood-
brain barrier, we believe that lenalidomide deserves further investigation either alone or in 
combination with chemotherapy as first-line treatment in patients with primary and secondary CNS 
lymphomas. 
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Figure 1. CSF evaluation at time of CNS relapse. 
	
	 	
		
	
